|
| Research progress in clinical application of lentinan anti-tumor therapy |
| Hits 1405 Download times 1943 Received:May 21, 2019 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2019.11.26 |
| Key Words
lentinan;tumor;clinical application;tumor immunity |
| Author Name | Affiliation | E-mail | | ZHANG Jing | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | SU Chang | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | tjsuchang@163.com | | JIA Yingjie | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | LI Xiaojiang | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | |
|
| Abstract
|
| Lentinan is a biological regulation section that inhibits tumor growth and enhancing immune function. A large number of animal experiments and clinical reports indicate that it has the function of regulating immune function and inhibiting tumor growth. Lentinan is widely used for anti-tumor adjuvant therapy,aiming to increasing the efficiency,decreasing the adverse side effects,modulating the immune responses and improving the quality of life. Therefore,this paper reviews the recent research progress of lentinan in clinical application which could provide new insights in the future study design. |
|
|
|
|
|
|
|
